查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103735

血管炎治療市場：全球市場預測，2026-2032年

Vasculitis Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血管炎治療市場將成長至 23.9 億美元，複合年成長率為 5.31%。

主要市場統計數據
基準年 2025 16.6億美元
預計年份：2026年 17.5億美元
預測年份 2032 23.9億美元
複合年成長率 (%) 5.31%

血管炎的治療正從廣泛的免疫抑制療法轉向以緩解為導向的精準醫療，以應對多種罕見的自體免疫和發炎性疾病，這些疾病會損害全身各器官的血管。血管炎治療市場的需求主要來自抗嗜中性白血球抗體相關性血管炎（AAV）、鉅細胞動脈炎（GCA）、大動脈炎、白塞病、IgA血管炎以及其他小、中、大血管疾病的巨大未滿足需求，因為延誤診斷可能導致腎衰竭、視力喪失、肺出血、神經病變、中風和心血管併發症。

實證治療方案仍主要圍繞糖皮質激素、Cyclophosphamide、Rituximab、胺基甲基葉酸、Azathioprine、Mycophenolate Mofetil以及某些高風險病例的血漿置換。然而，監管方面的突破，例如美國FDA批准利妥Rituximab用於治療顯微多發性血管炎，托珠單抗用於治療鉅細胞動脈炎，以及阿伐可泮作為重度活動性AAV的輔助性治療，正在改變治療領域的競爭格局。這些進展推動了對生物製藥、標靶免疫調節劑、非荷爾蒙療法、基於生物標記的監測以及多學科專業化治療的需求。

血管炎治療的變革性變化

血管炎治療領域最顯著的轉變是從以生存為中心的治療轉向長期維持器官功能和最佳化生活品質。美國風濕病學會 (ACR)、血管炎基金會、歐洲抗風濕病聯盟 (EULAR) 和 KDIGO 等組織的臨床指南越來越支持基於風險分層的誘導和維持治療策略，尤其是在伴有腎臟病變、疾病復發或危及生命的 AAV 病例中。

人工智慧（AI）的累積影響

人工智慧並非僅僅取代專家的判斷，而是正成為血管炎治療整個價值鏈中累積的驅動力。在診斷方面，機器學習可用於輔助識別電子健康記錄、實驗室指標、影像報告、病理觀察以及轉診前往往分散的症狀群等資訊模式。這一點尤其重要，因為血管炎的臨床表現可能與感染疾病、惡性腫瘤、血栓症和其他自體免疫疾病相似。

血管炎治療的關鍵區域見解

北美憑藉其先進的專科醫療網路、生物製藥的高使用率、完善的臨床試驗基礎設施以及已通過核准療法的快速推廣，仍然是血管炎治療領域領先的地區。美國透過學術血管炎中心、保險公司主導的專科藥房模式以及積極參與公共和行業主導的研究，推動了該地區的大部分創新。另一方面，加拿大則受益於其全民健保體系、省級報銷審查以及風濕病學和腎臟病學之間建立的合作關係。

全球市場關鍵群洞察

在主要經濟和地緣政治集團中，七國集團（G7）憑藉完善的醫保報銷機制、生物製藥的廣泛應用、先進的診斷技術以及學術臨床試驗網路，成為對高價值血管炎治療需求最為集中的地區。歐盟受益於跨境科學合作、歐洲藥品管理局（EMA）的集中監管流程以及對罕見疾病治療日益成長的關注，但各成員國的醫保報銷決策仍然影響著商業性可及性。

主要國家血管炎治療方法分析

美國是血管炎治療領域創新和商業化的重要中心，這得益於FDA批准的療法、罕見疾病研究網路、專科醫療中心以及獲取高度專業化藥物的途徑。加拿大緊追在後，擁有完善的臨床標準和公共健保報銷機制。墨西哥和巴西是拉丁美洲該領域最重要的市場，儘管風濕病領域的准入正在擴大，但生物製藥和標靶治療的定價挑戰仍然存在。

為行業領導者提供的實用建議

行業領導者應在其臨床和商業策略中優先考慮減重類固醇劑量、預防復發、保護腎臟、減少血管併發症以及患者報告結局。與競爭對手的差異化優勢將越來越依賴在真實臨床實踐中證明能夠降低累積糖皮質激素暴露量、維持緩解、提供更安全的長期維持治療、減少嚴重感染疾病並提高患者生活品質。

調查方法

本執行摘要採用二級研究框架編寫，優先考慮檢驗的臨床、監管和醫療保健資訊。主要資訊來源包括同行評審的醫學文獻、美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 的監管資訊、美國風濕病學會 (ACR)、血管炎基金會、歐洲抗風濕病聯盟 (EULAR) 和 KDIGO 的指南、臨床試驗註冊資訊、國家衛生技術評估文件以及公開的衛生政策相關資料。

結論：血管炎治療的未來

目前，血管炎的治療正朝著更具針對性和數據驅動的階段發展，其特點是減少類固醇用量、引入生物製藥、多學科診療以及更多地應用真實世界證據。雖然傳統的免疫抑制劑仍然必不可少，但能夠維持緩解、抑制復發、保護器官並降低治療毒性的療法正日益成為市場格局的重要組成部分。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 血管炎治療市場：依治療類型分類

  • 生物製劑
    • Rituximab
    • 腫瘤壞死因子抑制劑
  • 皮質類固醇
  • 免疫抑制劑
    • Azathioprine
    • Cyclophosphamide
    • 胺基甲基葉酸
    • Mycophenolate Mofetil
  • 血漿置換

第8章：血管炎治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第9章：血管炎治療市場：依疾病類型分類

  • ANCA相關性血管炎
  • 白塞氏症
  • 鉅細胞動脈炎
  • IgA血管炎
  • 大動脈炎

第10章：血管炎治療市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院
  • 專業醫療中心

第11章：血管炎治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 血管炎治療市場：依地區分類

  • 歐洲
  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 中東
  • 非洲

第13章：血管炎治療市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第14章 血管炎治療市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 英國
  • 印度
  • 法國
  • 加拿大
  • 巴西
  • 墨西哥
  • 義大利
  • 西班牙
  • 澳洲
  • 韓國
  • 俄羅斯

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GSK plc
  • AstraZeneca PLC
  • CSL Limited
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Celltrion, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Sandoz Group AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Grifols, SA
  • Octapharma AG
  • Biogen Inc.
  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Kedrion SpA
  • Amneal Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Limited
  • InflaRx GmbH
  • Intas Pharmaceuticals Limited
  • Kyverna Therapeutics, Inc.
  • Lupin Limited
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • UCB SA
  • Viatris Inc.
Product Code: MRR-C002B1C9976D

The Vasculitis Treatment Market is projected to grow by USD 2.39 billion at a CAGR of 5.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.66 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.39 billion
CAGR (%) 5.31%

Vasculitis treatment is moving from broad immunosuppression toward precision, remission-focused care for a heterogeneous group of rare autoimmune and inflammatory disorders that damage blood vessels across organs. The vasculitis treatment market is shaped by high unmet need in antineutrophil cytoplasmic antibody-associated vasculitis (AAV), giant cell arteritis (GCA), Takayasu arteritis, Behcet disease, IgA vasculitis, and other small-, medium-, and large-vessel conditions where delayed diagnosis can lead to kidney failure, vision loss, pulmonary hemorrhage, neuropathy, stroke, and cardiovascular complications.

Evidence-based care remains anchored in glucocorticoids, cyclophosphamide, rituximab, methotrexate, azathioprine, mycophenolate mofetil, and plasma exchange in selected high-risk scenarios. However, regulatory milestones have changed the competitive landscape, including U.S. FDA approvals of rituximab for granulomatosis with polyangiitis and microscopic polyangiitis, tocilizumab for GCA, and avacopan as an adjunctive therapy for severe active AAV. These advances are increasing demand for biologics, targeted immunomodulators, steroid-sparing regimens, biomarker-driven monitoring, and multidisciplinary specialty care.

Transformative Shifts in Vasculitis Care

The most important transformation in vasculitis care is the shift from survival-centered treatment to long-term organ preservation and quality-of-life optimization. Clinical guidelines from organizations such as the American College of Rheumatology and Vasculitis Foundation, EULAR, and KDIGO increasingly support risk-stratified induction and maintenance strategies, particularly in AAV with renal involvement, relapsing disease, or life-threatening manifestations.

Treatment innovation is also being driven by steroid-sparing approaches. Long-term glucocorticoid exposure is strongly associated with infection, diabetes, osteoporosis, cataracts, cardiovascular risk, and patient-reported treatment burden. As a result, clinicians, manufacturers, and payers are prioritizing therapies that demonstrate sustained remission, relapse prevention, reduced cumulative steroid dose, and measurable improvement in organ-specific outcomes.

At the same time, care delivery is becoming more integrated. Rheumatology, nephrology, pulmonology, dermatology, ophthalmology, neurology, pathology, and radiology teams are increasingly coordinated through vasculitis centers of excellence, real-world registries, and shared-care pathways. This evolution supports earlier diagnosis, standardized monitoring, and stronger evidence generation in rare disease populations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across the vasculitis treatment value chain rather than a stand-alone replacement for specialist judgment. In diagnosis, machine learning can support pattern recognition across electronic health records, laboratory trends, imaging reports, pathology findings, and symptom clusters that are often fragmented before referral. This is especially relevant because vasculitis presentations can mimic infection, malignancy, thrombosis, and other autoimmune diseases.

In clinical development, AI can improve feasibility modeling, site selection, eligibility screening, and patient-trial matching for rare vasculitis indications where recruitment is difficult. Natural language processing may help identify potential patients from unstructured clinical notes, while imaging analytics can assist in quantifying vascular inflammation in large-vessel vasculitis using modalities such as PET-CT, MRI, CT angiography, and ultrasound.

Commercially, AI can strengthen pharmacovigilance, adherence support, access analytics, and real-world evidence generation. Its near-term impact will be greatest when validated against expert-labeled datasets, integrated into regulated clinical workflows, and deployed with safeguards for bias, explainability, privacy, and clinician oversight.

Key Regional Insights in Vasculitis Treatment

North America remains a leading region for vasculitis treatment adoption due to advanced specialty networks, high biologic utilization, strong clinical trial infrastructure, and rapid uptake of approved therapies. The United States drives much of the region's innovation through academic vasculitis centers, payer-managed specialty pharmacy models, and active participation in public and industry-sponsored research, while Canada benefits from universal coverage frameworks, provincial reimbursement review, and established rheumatology-nephrology collaboration.

Europe is a mature and evidence-driven market supported by EULAR guidance, national health technology assessment systems, and strong registry culture. Germany, France, Italy, Spain, and the United Kingdom show significant demand for steroid-sparing biologics, although reimbursement timing and regional access pathways vary. Asia-Pacific is expanding as China, Japan, India, Australia, and South Korea improve autoimmune disease awareness, specialty referral pathways, and access to advanced immunology therapies; Japan's aging population is particularly relevant for GCA and other age-associated inflammatory conditions.

Latin America is progressing through improved specialist access in Brazil and Mexico, but biologic affordability, fragmented reimbursement, and diagnostic delays remain important barriers. The Middle East, especially GCC countries, is investing in tertiary hospitals and specialty care, supporting uptake of advanced therapies. Africa continues to face the greatest access constraints, with opportunities centered on diagnostic capacity, physician education, essential immunosuppressive availability, pathology services, and referral network development.

Key Group Insights Across Global Markets

Among major economic and geopolitical groups, the G7 represents the strongest concentration of high-value vasculitis treatment demand because of established reimbursement systems, biologic penetration, advanced diagnostics, and academic trial networks. The European Union benefits from cross-border scientific collaboration, centralized regulatory pathways through the European Medicines Agency, and a growing emphasis on rare disease strategies, although member-state reimbursement decisions continue to shape commercial access.

BRICS markets offer substantial long-term volume potential due to large populations and expanding specialty infrastructure, particularly in China, India, and Brazil. However, pricing pressure, uneven access to biologics, and variable diagnostic capacity require differentiated market access models. ASEAN markets are increasingly important as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines strengthen immunology services, but treatment adoption varies widely by income level, insurance coverage, and tertiary-care concentration.

The GCC is emerging as a premium specialty-care cluster supported by hospital modernization, public-sector healthcare investment, and demand for advanced rheumatology and nephrology services. NATO countries overlap significantly with North America and Europe, making them relevant for supply chain resilience, regulatory alignment, cold-chain reliability, and public-health preparedness for immunocompromised populations receiving vasculitis therapies.

Key Country Insights for Vasculitis Treatment

The United States is a major innovation and commercialization hub for vasculitis treatment, supported by FDA-approved therapies, rare disease research networks, specialist centers, and high specialty drug utilization. Canada follows with strong clinical standards and public reimbursement processes. Mexico and Brazil are the most important Latin American markets in this scope, with expanding rheumatology access but continued affordability challenges for biologics and targeted therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain sophisticated vasculitis care pathways, though access depends on national health technology assessment decisions and regional commissioning. Germany's specialist infrastructure and France's rare disease networks strengthen early diagnosis and follow-up, while the United Kingdom emphasizes evidence-based prescribing through NICE and NHS pathways. Russia has a sizeable patient base but faces access and supply variability linked to reimbursement dynamics and healthcare system fragmentation.

China and India represent important expansion opportunities because of large populations, increasing autoimmune disease recognition, and expanding hospital capacity, though diagnosis outside major cities remains uneven. Japan is a key developed market with strong relevance to age-associated vasculitis and high-quality clinical practice. Australia and South Korea combine advanced diagnostics, specialist care, and reimbursement structures that support adoption of evidence-backed therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize steroid-sparing efficacy, relapse prevention, renal protection, vascular complication reduction, and patient-reported outcomes in clinical and commercial strategy. Differentiation will increasingly depend on demonstrating reduced cumulative glucocorticoid exposure, durable remission, safer long-term maintenance, fewer serious infections, and improved quality of life in real-world settings.

Organizations should invest in biomarker strategies, companion diagnostic research, and registry partnerships to improve patient stratification and evidence generation. Market access teams need region-specific value dossiers that address hospitalization avoidance, dialysis prevention, vision preservation, infection reduction, reduced steroid-related toxicity, and productivity benefits. In emerging markets, tiered pricing, local partnerships, physician education, and diagnostic support programs can accelerate responsible access.

Digital and AI initiatives should focus on validated use cases such as earlier referral prompts, trial matching, adherence support, imaging quantification, and pharmacovigilance. Leaders that combine scientific credibility with payer-relevant evidence and equitable access models will be best positioned in the vasculitis treatment market.

Research Methodology

This executive summary is developed using a secondary research framework that prioritizes verified clinical, regulatory, and healthcare intelligence. Core sources include peer-reviewed medical literature, U.S. FDA and European Medicines Agency regulatory information, guideline publications from ACR, the Vasculitis Foundation, EULAR, and KDIGO, clinical trial registries, national health technology assessment documents, and publicly available healthcare policy resources.

The analysis triangulates disease epidemiology, treatment standards, drug approval history, reimbursement dynamics, regional healthcare infrastructure, and real-world care trends. Insights are interpreted through the lens of vasculitis treatment adoption, biologic and targeted therapy utilization, specialty-care readiness, and unmet clinical need. No unverified market sizing, market share, or unsupported forecasting claims are used; emphasis is placed on evidence-backed trends that are defensible for executive decision-making.

Conclusion: Future of Vasculitis Treatment

The vasculitis treatment landscape is entering a more targeted, data-driven phase defined by steroid-sparing therapy, biologic adoption, multidisciplinary care, and growing use of real-world evidence. While conventional immunosuppressants remain essential, the market is increasingly shaped by therapies that can sustain remission, reduce relapse, protect organs, and lower treatment toxicity.

Regional opportunity will depend on diagnostic capacity, reimbursement maturity, specialty access, and payer confidence in long-term value. Organizations that invest in differentiated clinical evidence, AI-enabled care support, and equitable access strategies can improve outcomes while strengthening competitive positioning in a rare but high-impact inflammatory disease category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
      • 4.3.1.1. Steroid-Sparing Treatment Goals Accelerate Demand for Targeted Immunology
      • 4.3.1.2. Biologic and Mechanism-Based Therapies Are Redefining Standard of Care
      • 4.3.1.3. Specialist-Center Expansion Improves Diagnosis, Adoption, and Therapy Persistence
      • 4.3.1.4. Demographic Aging and Digital Care Infrastructure Expand Treatable Demand
    • 4.3.2. Key Restraints
      • 4.3.2.1. High Specialty-Therapy Costs and Payer Controls Slow Broad Adoption
      • 4.3.2.2. Evidence Gaps and Safety Scrutiny Increase Regulatory and Physician Adoption Risk
    • 4.3.3. Key Opportunities
      • 4.3.3.1. Expand Evidence-Led Steroid-Sparing Regimens in ANCA-Associated Vasculitis
      • 4.3.3.2. Capture EGPA Biologic Growth Through Differentiated Patient and Physician Support
      • 4.3.3.3. Use Biosimilars to Broaden Biologic Access and Defend Health-System Budgets
    • 4.3.4. Key Challenges
      • 4.3.4.1. Fragmented Diagnosis and Rare-Patient Recruitment Limit Scalable Commercial Execution
      • 4.3.4.2. Geopolitical and Supply-Chain Volatility Raises Cost, Availability, and Compliance Risk
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vasculitis Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Rituximab
    • 7.2.2. Tumor Necrosis Factor Inhibitors
  • 7.3. Corticosteroids
  • 7.4. Immunosuppressants
    • 7.4.1. Azathioprine
    • 7.4.2. Cyclophosphamide
    • 7.4.3. Methotrexate
    • 7.4.4. Mycophenolate Mofetil
  • 7.5. Plasma Exchange

8. Vasculitis Treatment Market, by Administration Route

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Vasculitis Treatment Market, by Disease Type

  • 9.1. Introduction
  • 9.2. ANCA Associated Vasculitis
  • 9.3. Behcet Disease
  • 9.4. Giant Cell Arteritis
  • 9.5. IgA Vasculitis
  • 9.6. Takayasu Arteritis

10. Vasculitis Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Care Centers
  • 10.3. Clinics
  • 10.4. Hospitals
  • 10.5. Specialty Centers

11. Vasculitis Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Vasculitis Treatment Market, by Region

  • 12.1. Europe
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Middle East
  • 12.6. Africa

13. Vasculitis Treatment Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. ASEAN
  • 13.6. GCC

14. Vasculitis Treatment Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. Japan
  • 14.5. United Kingdom
  • 14.6. India
  • 14.7. France
  • 14.8. Canada
  • 14.9. Brazil
  • 14.10. Mexico
  • 14.11. Italy
  • 14.12. Spain
  • 14.13. Australia
  • 14.14. South Korea
  • 14.15. Russia

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Amgen Inc.
  • 16.2. F. Hoffmann-La Roche AG
  • 16.3. GSK plc
  • 16.4. AstraZeneca PLC
  • 16.5. CSL Limited
  • 16.6. Kissei Pharmaceutical Co., Ltd.
  • 16.7. Pfizer Inc.
  • 16.8. Celltrion, Inc.
  • 16.9. Teva Pharmaceutical Industries Ltd.
  • 16.10. Fresenius SE & Co. KGaA
  • 16.11. Sandoz Group AG
  • 16.12. AbbVie Inc.
  • 16.13. Takeda Pharmaceutical Company Limited
  • 16.14. Grifols, S.A.
  • 16.15. Octapharma AG
  • 16.16. Biogen Inc.
  • 16.17. Johnson & Johnson
  • 16.18. Novartis AG
  • 16.19. Sanofi SA
  • 16.20. Kedrion S.p.A.
  • 16.21. Amneal Pharmaceuticals, Inc.
  • 16.22. Bayer AG
  • 16.23. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 16.24. Bristol Myers Squibb Company
  • 16.25. Dr. Reddy's Laboratories Limited
  • 16.26. InflaRx GmbH
  • 16.27. Intas Pharmaceuticals Limited
  • 16.28. Kyverna Therapeutics, Inc.
  • 16.29. Lupin Limited
  • 16.30. Regeneron Pharmaceuticals, Inc.
  • 16.31. Sun Pharmaceutical Industries Limited
  • 16.32. UCB S.A.
  • 16.33. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULITIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VASCULITIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VASCULITIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUMOR NECROSIS FACTOR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUMOR NECROSIS FACTOR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUMOR NECROSIS FACTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AZATHIOPRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AZATHIOPRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AZATHIOPRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLOPHOSPHAMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLOPHOSPHAMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLOPHOSPHAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHOTREXATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METHOTREXATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHOTREXATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MYCOPHENOLATE MOFETIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYCOPHENOLATE MOFETIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MYCOPHENOLATE MOFETIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANCA ASSOCIATED VASCULITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANCA ASSOCIATED VASCULITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANCA ASSOCIATED VASCULITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BEHCET DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BEHCET DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BEHCET DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GIANT CELL ARTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GIANT CELL ARTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GIANT CELL ARTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IGA VASCULITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IGA VASCULITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IGA VASCULITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TAKAYASU ARTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TAKAYASU ARTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TAKAYASU ARTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. NATO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. G7 VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. G7 VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GCC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GERMANY VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. GLOBAL VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 303. GLOBAL VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025